Bank Of New York Mellon Corp Kinnate Biopharma Inc. Transaction History

Bank Of New York Mellon Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$5.26 - $12.19 $520,797 - $1.21 Million	99,011 New	99,011 $603,000
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $86,689 - $138,561	8,792 Added 9.93%	97,321 $1.16 Million
Q2 2022 Aug 15, 2022	SELL	$7.43 - $13.0 $33,375 - $58,396	-4,492 Reduced 4.83%	88,529 $1.12 Million
Q1 2022 May 11, 2022	SELL	$7.73 - $17.99 $10,180 - $23,692	-1,317 Reduced 1.4%	93,021 $1.05 Million
Q4 2021 Feb 11, 2022	BUY	$16.5 - $25.48 $451,242 - $696,827	27,348 Added 40.82%	94,338 $1.67 Million
Q3 2021 Nov 12, 2021	BUY	$17.81 - $24.87 $467,815 - $653,260	26,267 Added 64.5%	66,990 $1.54 Million
Q2 2021 Aug 11, 2021	BUY	$22.19 - $31.55 $109,995 - $156,393	4,957 Added 13.86%	40,723 $948,000
Q1 2021 May 13, 2021	BUY	$26.99 - $40.0 $965,324 - $1.43 Million	35,766 New	35,766 $1.11 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.